pISSN 1226-6051
eISSN 2508-786X

Table. 2.

Table. 2.

Gastrointestinal drug use by antibiotic class

n Penicillins 1st generation Cephalosporines 2nd generation Cephalosporines 3rd generation Cephalosporines Quinolones Sulfonamides Others
Patients without underlying GI disorders in the previous 6 months excluding the date of diagnosis of acute cystitis (Group A) Total, n (%) 1,544 189 (12.2%) 117 (7.6%) 624 (40.4%) 30 (1.9%) 430 (27.8%) 73 (4.7%) 81 (5.7%)
No GI drugs 368 38 (20.1%) 34 (29.1%) 120 (19.2%) 12 (40.0%) 110 (25.6%) 36 (49.3%) 18 (22.2%)
Patients with GI drugs 1,176 151 (79.9%) 83 (70.9%) 504 (80.8%) 18 (60.0%) 320 (74.4%) 37 (50.7%) 63 (77.8%)
Antiulcer agents 86 (45.5%) 57 (48.7%) 237 (38.0%) 12 (40.0%) 180 (41.8%) 19 (26.0%) 36 (44.4%)
GI regulators 59 (31.2%) 21 (17.9%) 244 (39.1%) 5 (16.7%) 113 (26.3%) 12 (16.4%) 25 (30.8%)
Both classes 6 (3.2%) 5 (4.3%) 23 (3.7%) 1 (3.3%) 26 (6.1%) 6 (8.3%) 2 (2.6%)
Patients without underlying GI disorders in the previous 6 months including the date of diagnosis of acute cystitis (Group B) Total, n (%) 552 58 (10.5%) 43 (7.8%) 191 (34.6%) 12 (2.2%) 168 (30.4%) 44 (8.0%) 36 (4.7%)
No GI drugs 321 32 (55.2%) 29 (67.4%) 99 (51.8%) 10 (83.3%) 100 (59.5%) 35 (79.5%) 16 (44.4%)
Patients with GI drugs 231 26 (44.8%) 14 (32.6%) 92 (48.2%) 2 (16.7%) 68 (40.5%) 9 (20.5%) 20 (55.6%)
Antiulcer agents 7 (12.2%) 7 (16.3%) 22 (11.5%) 1 (8.3%) 22 (13.1%) 5 (11.4%) 7 (19.4%)
GI regulators 19 (32.7%) 7 (16.3%) 70 (36.7%) 1(8.3%) 46 (27.4%) 5 (11.4%) 13 (36.1%)
Both classes 0 0 0 0 0 1 (2.8%) 0

Abbreviation: GI, gastrointestinal

Korean J Clin Pharm 2023;33:8-21 https://doi.org/10.24304/kjcp.2023.33.1.8
© 2023 Korean J Clin Pharm